Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD-AdNS3 Dendritic Cell Vaccine for Chronic Hepatitis C
NCT02309086Phase 2Terminated
- Sponsor
- Universidad de Navarra
- Start
- May 2011
- Primary completion
- May 2013
01
Overview
Phase 2, open-label, single-arm trial of CD-AdNS3 in hepatitis C (HCV), sponsored by Universidad de Navarra. Primary endpoints: Safety and tolerability determined by the evaluation of the number of participants with adverse events at 6 months and Liver safety assessed by blood analysis and Ultrasound at 6 months. Started May 2011; status: terminated.
02
Drugs
CD-AdNS3
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02309086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02309086.